Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

AstraZeneca cancer drug Sone-Ve granted priority review by US FDA

19th Nov 2026 11:21

(Alliance News) - AstraZeneca PLC on Thursday said its biologics license application for cancer treatment sonesitatug vedotin, or Sone-Ve, has been accepted and granted priority review by the US Food & Drug Administration.

The Cambridge, England-based pharmaceuticals firm said the approval is for second and later-line treatment of patients with locally advanced or metastatic gastric cancer, gastroesophageal junction cancer or oesophageal adenocarcinoma.

The FDA grants priority review to applications for medicines that, if approved, would offer significant improvements over available treatment options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance.

The prescription drug user fee act date, the FDA action date for their regulatory decision, is anticipated during the second quarter of 2027.

The approval was based on Clarity-Gastric01 phase III trial results which showed Sone-Ve reduced the risk of death by 42% in the second and later line setting.

Sone-Ve has received orphan drug designation from the US Food & Drug Administration and the European Commission for the treatment of gastric and GEJ cancers. It has also received breakthrough designation in China for the second line treatment of gastric cancer. Regulatory applications are currently under review in the EU, China and several other countries based on the trial results.

"This priority review of our submission speaks to the significant potential of this medicine and accelerates the ability to bring forward a new targeted approach and alternative to traditional chemotherapy for thousands of patients in the US," said Susan Galbraith, executive vice president, Oncology Haematology R&D, AstraZeneca.

Shares in AstraZeneca were down 1.2% at 13,484.00 pence each in London on Thursday.

By Jeremy Cutler, Alliance News reporter

Comments and questions to [email protected]

Copyright 2026 Alliance News Ltd. All Rights Reserved.


Related Shares:

Astrazeneca
FTSE 100 Latest
Value10,506.58
Change-44.59